Regulation of Peripheral Neuropathic Pain by B Cells

B 细胞对周围神经病理性疼痛的调节

基本信息

  • 批准号:
    10588250
  • 负责人:
  • 金额:
    $ 62.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-15 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Effective treatments are elusive for the majority of patients with neuropathic pain, which is reflective of the incomplete knowledge of the underlying mechanisms. Our proposal will advance mechanistic understanding of peripheral neuropathic pain maintenance by investigating the differentiation and function of B cells after peripheral nerve injury. Our long-term goal is to harness the disease-modifying potential of neuroimmune signaling to treat neuropathic pain. As a step toward achieving this goal, the overall objective of this application is to discover if and how B cells cause neuropathic pain after peripheral nerve injury. Our central hypothesis is that peripheral nerve injury induces differentiation of B cells into plasma cells. The plasma cells secrete autoantibodies that form complexes with autoantigens which maintain neuropathic pain by signaling through the activating Fc gamma receptor (FcγR) subtypes (I, III, IV) along the pain neuraxis. We propose that insufficient efferocytosis (deficient non-inflammatory clearance of apoptotic cells, leading to release of Danger Associated Molecular Patterns (DAMPs)) at the site of nerve injury, triggers autoimmune B cell differentiation. This hypothesis is based on strong evidence that plasma cells are pro-nociceptive, as we show that either constitutive deficiency or pharmacological depletion of differentiating B cells protects male and female mice from neuropathic pain. Our data also reveal that insufficient efferocytosis leads to B cell differentiation, as pharmacological stimulation of efferocytosis at the time of peripheral nerve injury reduces immunoglobulin G (IgG) deposits in the spinal dorsal horn. The rationale for testing our hypothesis is that deciphering this previously overlooked adaptive immune response to peripheral nerve injury will reveal new and tractable therapeutic targets for neuropathic pain. To accomplish the overall objective of this application, we will test the central hypothesis in a mouse model of peripheral nerve injury across the following specific aims: 1) Define the function of B cell differentiation after peripheral nerve injury. Validation studies will be performed in a piglet model of peripheral injury, and in biological samples obtained from patients with lumbar radiculopathy; 2) Identify whether FcγR signaling maintains neuropathic pain; and, 3) Determine whether insufficient efferocytosis induces B cell differentiation leading to neuropathic pain. The proposed studies take a multidisciplinary approach, including pharmacologic and genetic manipulations, flow cytometry, in situ hybridization, adoptive transfer, and assessment of evoked and operant pain behaviors. As efferocytosis and downstream plasma cell differentiation have not been previously implicated in traumatic neuropathic pain, our proposal is highly innovative and is expected to expand our paradigm for neuroimmune regulation of peripheral neuropathic pain. The results will have significant impact on the treatment of peripheral neuropathic pain by revealing new sites for therapeutic intervention.
项目总结 对于大多数神经病理性疼痛的患者来说,有效的治疗是难以捉摸的,这反映了 对潜在机制的不完全了解。我们的建议将推进对 外周神经病理性疼痛维持的B细胞分化和功能研究 周围神经损伤。我们的长期目标是利用神经免疫的疾病修正潜力。 治疗神经病理性疼痛的信号。作为实现这一目标的一步,此应用程序的总体目标 是为了发现外周神经损伤后B细胞是否以及如何引起神经病理性疼痛。我们的中心假设是 周围神经损伤诱导B细胞分化为浆细胞。浆细胞分泌 自身抗体与自身抗原形成复合体,通过信号转导途径维持神经病理性疼痛 激活Fcγ受体(FcγR)亚型(I、III、IV)。我们认为,这是不够的 泡出(缺乏对凋亡细胞的非炎症性清除,导致相关危险的释放 神经损伤部位的分子模式(DAMPS),触发自身免疫B细胞分化。这 这一假说是建立在浆细胞具有促伤害性的强有力证据的基础上的,因为我们证明了 分化B细胞的缺乏或药物耗尽保护雄性和雌性小鼠免受神经病变的影响 疼痛。我们的数据还表明,泡吞噬作用不足会导致B细胞分化,就像药理学上的 周围神经损伤时刺激胞吐减少免疫球蛋白G(Ig G)沉积 脊椎背角。检验我们假设的基本原理是,破译这一先前被忽视的适应性 周围神经损伤的免疫反应将为神经病提供新的、易处理的治疗靶点 疼痛。为了实现本应用程序的总体目标,我们将在小鼠模型中测试中心假设 跨以下特定目标的周围神经损伤:1)明确B细胞分化后的功能 周围神经损伤。验证研究将在周围损伤的仔猪模型上进行,并在生物学上进行 取自腰神经根病患者的样本;2)鉴定FcγR信号是否保持 神经病理性疼痛;以及,3)确定泡腾作用不足是否诱导B细胞分化导致 神经性疼痛。拟议的研究采取了多学科方法,包括药理学和遗传学。 操作,流式细胞术,原位杂交,过继转移,以及诱发和可操作的评估 疼痛行为。因为之前还没有涉及到胞吐和下游浆细胞分化 在创伤性神经性疼痛方面,我们的建议具有很高的创新性,并有望扩展我们的研究范式 周围神经病理性疼痛的神经免疫调节。结果将对治疗产生重大影响 通过揭示新的治疗干预部位来研究周围神经病理性疼痛。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter M Grace其他文献

Peter M Grace的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter M Grace', 18)}}的其他基金

Regulation of Peripheral Neuropathic Pain by B Cells
B 细胞对周围神经病理性疼痛的调节
  • 批准号:
    10417954
  • 财政年份:
    2022
  • 资助金额:
    $ 62.66万
  • 项目类别:
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain
PQ12 靶向 HDAC6 治疗化疗引起的神经病变和化疗脑
  • 批准号:
    10376221
  • 财政年份:
    2018
  • 资助金额:
    $ 62.66万
  • 项目类别:
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain
PQ12 靶向 HDAC6 治疗化疗引起的神经病变和化疗脑
  • 批准号:
    10685944
  • 财政年份:
    2018
  • 资助金额:
    $ 62.66万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 62.66万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 62.66万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 62.66万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.66万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 62.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 62.66万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 62.66万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 62.66万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 62.66万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 62.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了